Sativex in Canada
In Canada, as well as being approved for the treatment of spasticity due to multiple sclerosis, Sativex is also approved for symptomatic relief of neuropathic pain in Multiple Sclerosis and as adjunctive analgesic treatment in patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain.
The following documents on Sativex® are available on the Bayer Canada website and are intended for use only by medical professionals and patients resident in Canada:
For information on Sativex from the website of Health Canada, the Canadian regulatory authority, please click here.
For enquiries regarding Sativex in Canada please contact Bayer Canada, GW’s marketing partner in Canada:
Tel: (1) 800 265 7382
Fax: (1) 866 232 0565